INTRODUCTION {#s1}
============

Campylobacter jejuni is one of the major causes of bacterial diarrhea worldwide, and infection leads to a high rate of childhood mortality in low- to middle-income countries (LMICs) ([@B1], [@B2]). Campylobacteriosis is characterized by watery or bloody diarrhea, fever, and abdominal pain and can persist from a few days to several weeks. Occasionally, serious postinfectious sequelae, such as Guillain-Barré syndrome, irritable bowel syndrome, and reactive arthritis, can follow diarrheal disease ([@B3]). In LMICs, children under 2 years of age are particularly susceptible to *Campylobacter*-induced diarrhea, and asymptomatic carriage of *Campylobacter* species in healthy children is also common ([@B3]). C. jejuni can disrupt intestinal tight junctions and induces gut leakage and systemic inflammation ([@B4], [@B5]). Both symptomatic and asymptomatic *Campylobacter* infections are reported to be associated with growth stunting in children ([@B6], [@B7]).

The *Campylobacter* genus contains 31 species (<http://www.bacterio.net/campylobacter.html>), many of which are known pathogens in humans ([@B8]). C. jejuni and Campylobacter coli are among the most commonly detected species associated with gastroenteritis, but emerging *Campylobacter* species, such as Campylobacter upsaliensis, Campylobacter lari, and Campylobacter hyointestinalis, are receiving more attention due to their increasing association with human diseases, likely resulting from improved isolation and detection techniques ([@B8]). For example, some *Campylobacter* spp., including C. hyointestinalis and Campylobacter fetus, are sensitive to antimicrobial agents used in traditional *Campylobacter*-selective agar and are isolated more frequently using the Cape Town protocol with antibiotic-free blood agar and H~2~ enrichment ([@B9]).

Contaminated foods and water are considered the main sources of *Campylobacter* infections in LMICs, and the risk of *Campylobacter*-associated diarrhea in children has been suggested to be reduced by several factors, including breastfeeding ([@B7]). In infants \<1 year of age, the mother's milk not only provides nutrition but also supports the establishment of a healthy gut microbiota and the development of a robust immune system ([@B10]). Human milk contains antibodies against various pathogens, including *Campylobacter*, and human milk oligosaccharides (HMOs), particularly fucosyloligosaccharides such as 2′-fucosyllactose, have been reported to inhibit some C. jejuni strains from binding to intestinal epithelial cells and colonizing mouse models ([@B11], [@B12]). Also, HMOs stimulate the growth of beneficial bacteria, such as *Bifidobacterium*, which provide a variety of health benefits, including competition with enteric pathogens such as *Campylobacter* ([@B13]).

Children who are not breastfed do not receive protective antibodies or HMOs and are thus at a higher risk for infection, particularly diarrheal disease ([@B3], [@B14]). Yet 85% of children had *Campylobacter*-positive stools by 1 year of age in LMICs where breastfeeding is common ([@B7], [@B15]). Our previous studies have shown that \>50% of sequenced C. jejuni and C. coli isolates possess a *fuc* locus (*cj0480c* to *cj0489*) ([@B16]) for [l]{.smallcaps}-fucose metabolism, providing strains such as C. jejuni NCTC 11168 with a competitive advantage in the colonization of a piglet model for diarrheal disease ([@B16], [@B17]). [l]{.smallcaps}-Fucose can be released from fucosylated HMOs by several gut microbes, including *Bacteroides* and *Bifidobacterium* species ([@B18][@B19][@B20]); thus, it is possible that human milk may actually provide a rich carbon source to promote the growth of *Campylobacter* strains capable of metabolizing [l]{.smallcaps}-fucose. This hypothesis had not been previously explored since C. jejuni and C. coli were considered to be asaccharolytic, relying solely on amino acids and tricarboxylic acid (TCA) cycle intermediates for carbon sources ([@B21]). Now, with the discovery that many *Campylobacter* isolates metabolize [l]{.smallcaps}-fucose, together with the observation that free [l]{.smallcaps}-fucose levels can reach 4 to 5 mg/g feces in breastfed children ([@B22]) and reports that [d]{.smallcaps}-glucose is also abundant in feces of breastfed children ([@B22]) and that ∼1.7% of sequenced C. jejuni and C. coli strains possess the Entner-Doudoroff (ED) pathway for glucose utilization ([@B23]), we sought to examine the relationship between breastfeeding and *Campylobacter* infections to better understand the process of *Campylobacter*-induced diarrhea in infants.

To measure the burden and bacterial etiology of diarrheal disease in children under 5 years of age in LMICs, the Global Enterics Multicenter Study (GEMS) was conducted in seven countries in sub-Saharan Africa (The Gambia, Kenya, Mali, and Mozambique) and South Asia (Bangladesh, India, and Pakistan) ([@B24]). Liu et al. found that together with other common pathogens, C. jejuni and C. coli were major causes of diarrhea in this age group ([@B2]). To examine the relationship between *Campylobacter* infection and breastfeeding in infants \<1 year of age in the GEMS data set at a molecular level, we applied molecular techniques to examine the relative abundances of campylobacters and other resident gut microbes in asymptomatic and symptomatic *Campylobacter* infections. We also screened the C. jejuni and C. coli isolates for their ability to utilize [l]{.smallcaps}-fucose and [d]{.smallcaps}-glucose and assessed whether this correlated with diarrheal disease. Through these studies, we identified a new *Campylobacter* species that is present in stool samples of infants from multiple countries and is as prevalent as C. coli.

RESULTS {#s2}
=======

Data description. {#s2.1}
-----------------

Our study included a total of 233 fecal DNA samples from symptomatic and asymptomatic *Campylobacter*-infected infants \<1 year of age that were collected at seven sites (The Gambia, Kenya, Mali, Mozambique, Bangladesh, India, and Pakistan), with infants either exclusively or not breastfed (see [Fig. S1](#figS1){ref-type="supplementary-material"} and [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material). Of these 233 samples, 128 were from symptomatic infections (cases) and 105 were from asymptomatic infections (controls); 142 infants were exclusively breastfed, while 91 were not breastfed at the time of stool collection; 110 were 0 to 5 months old, while 123 were 6 to 11 months old; and 111 had moderate-to-severe diarrhea (MSD), while 17 had less-severe diarrhea (LSD).
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Flow diagram illustrating study activities. Download FIG S1, TIF file, 1.3 MB.
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Characteristics of study subjects with symptomatic or asymptomatic *Campylobacter* infections. Download Table S1, DOCX file, 0.01 MB.
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In 84.12% of the infants, comorbidities with other diarrheal pathogens were identified ([Fig. S2](#figS2){ref-type="supplementary-material"}), including viruses (astrovirus, norovirus, adenovirus, rotavirus, and sapovirus), other bacteria (*Aeromonas*, Bacteroides fragilis, Clostridium difficile, Escherichia coli, Helicobacter pylori, *Shigella*, *Salmonella* \[nontyphoidal\], and *Vibrio*), and parasites (*Giardia*, *Entamoeba*, and *Cryptosporidium*). Comorbidities with viruses were found in 33.48% of the infants, comorbidities with other bacteria were found in 66.95% of the infants, and comorbidities with parasites were found in 22.75% of the infants.
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Coinfection with other diarrheal pathogens, including viruses (astrovirus, norovirus, adenovirus, rotavirus, and sapovirus), other bacteria (*Aeromonas*, Bacteroides fragilis, Clostridium difficile, Escherichia coli, Helicobacter pylori, *Shigella*, *Salmonella* \[nontyphoidal\], and *Vibrio*), and parasites (*Giardia*, *Entamoeba*, and *Cryptosporidium*), in addition to *Campylobacter*. Percent values are the proportions in *Campylobacter*-infected infants. Download FIG S2, TIF file, 0.8 MB.
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The V6-V8 hypervariable region of the 16S rRNA gene was amplified from 229 samples and sequenced using the Illumina MiSeq platform at the University of Georgia Genomics and Bioinformatics Core; 4 of the 233 samples did not have amplification products and were not sequenced, and all 4 had MSD, with exclusive breastfeeding (2 samples) or no breastfeeding (2 samples). Of the 229 sequenced samples, 140 were from infants who were exclusively breastfed (diarrhea, *n* = 75; no diarrhea, *n* = 65), and 89 were from infants who were not breastfed (diarrhea, *n* = 49; no diarrhea, *n* = 40) at the time of stool collection. A total of 2,899 different amplicon sequence variants (ASVs) were obtained, with a median of 22,244 sequences per sample. Of the 229 samples, a random subset of 67 was amplified using the V4 hypervariable region of the 16S rRNA gene for additional confirmation.

A total of 142 C. jejuni and C. coli strains isolated from the fecal samples (1 isolate per sample) were tested for [l]{.smallcaps}-fucose utilization ([@B24], [@B25]). Of these 142 strains, 80 were from symptomatic infants (exclusively breastfed, *n* = 51; nonbreastfed, *n* = 29), and 62 were from asymptomatic infants (exclusively breastfed, *n* = 32; nonbreastfed, *n* = 30).

Compositional variations of fecal microbiota in cases and controls. {#s2.2}
-------------------------------------------------------------------

The Shannon index was calculated to measure the fecal microbial diversity ([Fig. 1A](#fig1){ref-type="fig"}) and showed that infants with diarrhea, with or without breastfeeding, had significantly lower fecal microbial diversity (*P \< *0.01) than asymptomatic infants. Nonbreastfed asymptomatic infants demonstrated the highest fecal diversity (*P \< *0.001), with fecal diversity within the exclusively breastfed asymptomatic infants being intermediate between the two groups (*P \< *0.01).

![Fecal microbiome in symptomatic and asymptomatic *Campylobacter* infections in infants \<1 year of age. (A) Microbial diversities (Shannon index) in different groups. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers. (B) Microbial compositions of fecal samples from cases and controls with breastfeeding (BF) or no breastfeeding (No BF) (V6-V8 of 16S rRNA). P, F, A, and B refer to phyla (P, *Proteobacteria*; F, *Firmicutes*; A, *Actinobacteria*; B, *Bacteroidetes*). (C) Microbial composition of fecal samples from cases and controls with breastfeeding or no breastfeeding (V4 of 16S rRNA). (D) Proportions of *Campylobacter* species at the individual-child level. Each of the bars represents one individual subject, and different *Campylobacter* species are shown in different colors. (E) Average *Campylobacter* abundance in each group. NS, not statistically significant; \*, *P* \< 0.05; \*\*\*, *P* \< 0.001; \*\*\*\*, *P* \< 0.0001.](mSphere.00735-19-f0001){#fig1}

The proportional abundance of taxa comprising each fecal microbiome was determined by sequencing the 16S rRNA V6-V8 hypervariable regions from each sample ([Fig. 1B](#fig1){ref-type="fig"}). This analysis showed that *Proteobacteria* were the most abundant in infants with diarrhea, while the *Firmicutes* were the most abundant in the controls ([Fig. S3A](#figS3){ref-type="supplementary-material"} and [B](#figS3){ref-type="supplementary-material"}). *Escherichia* and *Shigella* were the most abundant in all groups regardless of diarrheal status and breastfeeding; however, in infants who were not breastfed, the abundance of *Escherichia-Shigella* in cases (48.1%) was significantly higher than in controls (17.0%), while in exclusively breastfed infants, the difference was not statistically significant (40.1% in cases and 28.6% in controls) ([Table S2](#tabS2){ref-type="supplementary-material"}). Genera with significant differences between cases and controls are shown in [Table S2](#tabS2){ref-type="supplementary-material"}.
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Fecal microbiome in symptomatic and asymptomatic *Campylobacter* infections of infants \<1 year of age. (A) Microbial composition of fecal samples in cases and controls with or without breastfeeding at the phylum level (V6-V8 of 16S rRNA). (B) Microbial composition of fecal samples in cases and controls with or without breastfeeding at the phylum level (V4 of 16S rRNA). (C to J) Proportion of *Campylobacter* in the fecal microbiome at the individual-child level and average in each country as determined by 16S rRNA sequencing (V6-V8 regions). Each of the bars represents one individual, and different *Campylobacter* species are shown in the colors indicated. (C to F) Individual levels per country. (G to J) Averages per country. BD, Bangladesh; GM, The Gambia; KE, Kenya; MZ, Mozambique. (K and L) Proportion of *Campylobacter* in the fecal microbiome at the individual level in different age groups (0 to 5 months \[K\] and 6 to 11 months \[L\]). (I) Proportions of *Campylobacter* in fecal microbiomes between dysenteric and nondysenteric diarrheal cases. Download FIG S3, TIF file, 1.4 MB.
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Significantly different genera between cases and controls. Download Table S2, DOCX file, 0.01 MB.
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The V4 hypervariable region of the 16S rRNA gene amplifies *Bifidobacterium* effectively ([@B26], [@B27]), and a higher proportion of *Bifidobacterium* in exclusively breastfed than in nonbreastfed infants was observed following sequencing of the V4 hypervariable region ([Fig. 1C](#fig1){ref-type="fig"}). The *Bifidobacterium* genus is the most abundant in exclusively breastfed infants, but a higher abundance of *Escherichia-Shigella* was still found in cases (50.01%) than in controls (15.22%) with no breastfeeding (not statistically significant due to the smaller sample size of the V4 data set).

The relative abundance of *Campylobacter* was negatively correlated with several gut microbes, including *Dorea*, *Blautia*, *Klebsiella*, *Erysipelatoclostridium*, *Enterobacter*, *Faecalibacterium*, *Enterococcus*, *Collinsella*, the Ruminococcus gnavus group, *Lactococcus*, and *Anaerostipes*, and these gut microbes were positively correlated with each other ([Table S3](#tabS3){ref-type="supplementary-material"}).
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Correlations between *Campylobacter* and gut microbes. Download Table S3, DOCX file, 0.01 MB.
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Relative abundance of *Campylobacter* in symptomatic and asymptomatic infants. {#s2.3}
------------------------------------------------------------------------------

Although *Campylobacter* strains were isolated from all the fecal samples included in our study, 16S rRNA sequencing (V6-V8 regions) of the fecal DNA detected a fraction of them (cases with exclusive breastfeeding, 61/75; controls with exclusive breastfeeding, 31/65; cases with no breastfeeding, 34/49; controls with no breastfeeding, 10/40). As shown in [Fig. 1D](#fig1){ref-type="fig"} and [E](#fig1){ref-type="fig"}, the 16S rRNA of *Campylobacter* had \>0.99 identity value to C. jejuni, C. coli, C. lari, C. hyointestinalis, C. upsaliensis, and other campylobacters. A greater abundance of *Campylobacter* species was found in cases with breastfeeding (∼10%) than in other groups ([Fig. 1B](#fig1){ref-type="fig"}). Consistent with results obtained from sequencing the V6-V8 rRNA regions, the results with the V4 regions ([Fig. 1C](#fig1){ref-type="fig"}) showed that *Campylobacter* species are also more abundant in cases with breastfeeding (∼10%) than in all other groups (not statistically significant because of the smaller V4 sample size).

The relative abundance of *Campylobacter* in the fecal microbiome was highly variable in each group ([Fig. 1D](#fig1){ref-type="fig"}). In cases with breastfeeding, the highest abundance of *Campylobacter* was in one child with 83% of the fecal microbiome comprised of one strain with 0.99 identity value to C. hyointestinalis subsp. *lawsonii*/uncultured *Campylobacter* by 16S rRNA sequencing. Our results clearly indicate that exclusively breastfed infants with diarrheal symptoms had statistically the highest abundance of campylobacters compared to other groups, including nonbreastfed cases ([Fig. 1E](#fig1){ref-type="fig"}). Among nonbreastfed infants, cases had higher levels of *Campylobacter* than controls ([Fig. 1E](#fig1){ref-type="fig"}). When comparing controls with and those without breastfeeding, exclusively breastfed infants had higher *Campylobacter* levels than nonbreastfed infants, but the results were not statistically significant ([Fig. 1E](#fig1){ref-type="fig"}). Similar trends were found when the data were examined for different sites and ages ([Fig. S3C](#figS3){ref-type="supplementary-material"} to [H](#figS3){ref-type="supplementary-material"}).

Fucose metabolism in *Campylobacter* strains isolated from GEMS. {#s2.4}
----------------------------------------------------------------

Despite previous research suggesting that breastfeeding protects against C. jejuni-induced diarrhea ([@B11], [@B28]), reports from studies such as GEMS and MAL-ED indicated that a large proportion of breastfed children with diarrhea were *Campylobacter* positive, and our results unexpectedly showed even higher proportions of this genus in breastfed infants than in nonbreastfed infants. C. jejuni and C. coli were isolated in the original GEMS using selective plates for these two species ([@B25]). To assess whether there were any correlations between C. jejuni and C. coli abundances and carbohydrate metabolism, PCR screening for the fucose permease gene *fucP* was done. We used nested colony PCR for the *fucP* gene (with the 16S rRNA gene as a control) to screen for strains with the operon for fucose metabolism ([Fig. 2A](#fig2){ref-type="fig"}). The subset of isolates that were PCR positive was subsequently tested in growth assays in limited growth medium supplemented with [l]{.smallcaps}-fucose to confirm that they possessed a functional pathway ([Fig. 2B](#fig2){ref-type="fig"}). The results indicate that in nonbreastfed infants, approximately 50% of the strains were fucose utilizing versus nonutilizing (*P = *0.5775 and *P = *0.4652 for cases and controls, respectively), but in breastfed infants, significantly fewer fucose-utilizing strains (33% and 22% in cases and controls, respectively; *P \< *0.05) were found ([Fig. 2C](#fig2){ref-type="fig"}). Previous studies suggested that there is a negative correlation between the possession of the fucose metabolic locus and the γ-glutamyl transpeptidase (GGT) gene (*ggt*), which provides the strain the ability to utilize glutamine and glutathione ([@B29]). Since glutamine is one of the most abundant free amino acids in breast milk ([@B30]), we screened for the *ggt* gene in all strains and found that only 15 of 137 (11%) screened strains possessed the *ggt* gene, 12 of 79 (15%) in strains lacking *fucP* and 3 of 58 (5%) *fucP^+^* strains. For the utilization of [d]{.smallcaps}-glucose, 25% of strains were randomly selected and tested in growth assays using limited growth medium supplemented with [d]{.smallcaps}-glucose, and none of the tested strains showed enhanced growth in glucose.

![Investigation of the relationship between fucose metabolism and *Campylobacter* infection in GEMS. (A) A PCR screen for the fucose permease gene *fucP* was carried out for all samples, and a representative gel is shown. (B) Verification of the *fucP* colony PCR results to compare the abilities to metabolize fucose and show growth enhancement. Values shown are means (*n* = 3), and error bars represent 1 standard deviation (*fucP*^+^ strains are highlighted in boldface type). White, control; black, [l]{.smallcaps}-fucose addition. (C) Pie charts comparing the correlations between fucose metabolism and the isolated *Campylobacter* strains. Black, [l]{.smallcaps}-fucose-utilizing strains; white, non-[l]{.smallcaps}-fucose-utilizing strains. *P* values were determined by chi-squared testing compared to 50%.](mSphere.00735-19-f0002){#fig2}

A putative new *Campylobacter* species, "*Candidatus* Campylobacter infans." {#s2.5}
----------------------------------------------------------------------------

Multiplex PCR of the lipid A biosynthesis gene *lpxA* was used to confirm the presence of C. jejuni, C. coli, and C. upsaliensis identified by 16S rRNA sequencing ([@B31]). However, no molecular identification method was available for C. hyointestinalis, and only one C. hyointestinalis subsp. *lawsonii* genome was present in GenBank (accession number [CP015576](https://www.ncbi.nlm.nih.gov/nuccore/CP015576)), so we sequenced nine additional C. hyointestinalis subsp. *lawsonii* strains ([@B32]), and together with the genome of C. hyointestinalis subsp. *hyointestinalis* (GenBank accession number [NZ_CP015575.1](https://www.ncbi.nlm.nih.gov/nuccore/NZ_CP015575.1)), we designed a primer specific for the C. hyointestinalis *lpxA* gene of both subspecies to be used for multiplex PCR. The revised *lpxA* multiplex PCR was performed on the known C. hyointestinalis strains ([Fig. S4A](#figS4){ref-type="supplementary-material"}) and applied to the GEMS fecal DNA samples that were putatively designated to belong to this species by 16S rRNA sequencing ([Fig. S4B](#figS4){ref-type="supplementary-material"}). Only samples G9, G21, and G22 have the expected 285-bp product out of the predicted 26 GEMS fecal samples and were confirmed to contain C. hyointestinalis, suggesting that the other campylobacters identified as C. hyointestinalis subsp. *lawsonii*/uncultured *Campylobacter* by 16S rRNA sequencing may actually be a new species. One of the 26 infants (G1) ([Fig. S4C](#figS4){ref-type="supplementary-material"}) had prolonged diarrhea for 9 days, and 83.6% of the fecal microbiome was comprised of this species, with no other *Campylobacter* species being detected by 16S rRNA analysis, although one C. jejuni strain was isolated from the fecal sample. Metagenomic sequencing of this fecal DNA sample was performed, and assembly of the Illumina reads yielded 6,058 total contigs and 75 contigs identified as *Campylobacter*, of which 56 were larger than 5,000 bp. Overall, the metagenomic analysis of the fecal sample found the dominant clusters of orthologous groups (COGs) to be associated with functions in metabolism, information storage and processing, and cellular processes and signaling, and in particular, 10.3% of sequence reads were associated with protein metabolism ([Fig. S5A](#figS5){ref-type="supplementary-material"} and [B](#figS5){ref-type="supplementary-material"}). While 16S rRNA sequencing found a higher percentage of the fecal microbiome composition to be *Campylobacter* (83.6%), metagenomic analysis confirmed at the order level (74.3%) and genus level (66.6%) that it was the dominant member of the microbial community ([Fig. S5C](#figS5){ref-type="supplementary-material"} to [E](#figS5){ref-type="supplementary-material"}). Furthermore, 33.8% of all the sequence data that were assembled into contigs particularly \>10 kb were identified as *Campylobacter* ([Fig. S5F](#figS5){ref-type="supplementary-material"}), with an average of 76× coverage for these contigs, which further demonstrated that it was the major genus present in the fecal microbiome and provided sufficient coverage for genome assembly. BLASTP analysis of the 1,476 putative coding sequences identified in the 75 *Campylobacter* contigs indicated that the *Campylobacter* species present in this fecal sample was not one of the current validly described *Campylobacter* taxa; however, 72.8% (1,074/1,476) of the matches showed strong similarity to proteins from members of the C. fetus group (i.e., C. fetus, C. hyointestinalis, C. lanienae, and C. iguaniorum). Data from core gene/protein phylogenetic analyses ([Fig. 3A](#fig3){ref-type="fig"} and [B](#fig3){ref-type="fig"}) and average nucleotide identities (ANI) ([Fig. 3C](#fig3){ref-type="fig"}) are consistent with these results, suggesting that the *Campylobacter* strain in this fecal sample (referred to here as "*Candidatus* Campylobacter infans") represents a novel *Campylobacter* species ([Fig. 3](#fig3){ref-type="fig"}) that is related to, but distinct from, C. fetus, C. hyointestinalis, *C. lanienae*, and *C. iguaniorum*.

![Identification of a new *Campylobacter* species. (A and B) Sequences of 20 core genes from various *Campylobacteraceae* or their cognate proteins were concatenated and aligned using CLUSTALX. Included in the alignment were the same 20 concatenated genes or proteins extracted from the metagenomic sequences obtained from a fecal DNA sample containing 83% *Campylobacter* sequences ("*Candidatus* Campylobacter infans"). The dendrograms were constructed using the neighbor-joining algorithm and the Kimura two-parameter (gene set) (A) or Poisson (protein set) (B) distance estimation method. Bootstrap values of \>75%, generated from 500 replicates, are shown at the nodes. (C) Average nucleotide identity (ANI) of "*Candidatus* Campylobacter infans" among known related bacteria, including *Campylobacter*, *Sulfurimonas*, *Arcobacter*, *Sulfurospirillum*, and *Helicobacter* species.](mSphere.00735-19-f0003){#fig3}

10.1128/mSphere.00735-19.4

\(A\) Multiplex PCR to differentiate *Campylobacter* species using the *lpxA* gene. Lanes: 1, mixture of C. coli, C. jejuni, C. hyointestinalis (both subspecies), C. lari subsp. *lari*, and C. upsaliensis, with C. fetus as a control; 2, C. coli (391 bp); 3, C. jejuni (331 bp); 4, C. hyointestinalis subsp*. hyointestinalis* (285 bp); 5, C. hyointestinalis subsp. *lawsonii* (285 bp); 6, C. lari (233 bp); 7, C. upsaliensis (206 bp); 8, C. fetus (no product); 9 DNA ladder; 10 to 16, C. hyointestinalis subsp. *lawsonii* strains (285 bp). (B) PCR of the C. hyointestinalis *lpxA* gene from 26 GEMS fecal DNA samples possibly containing C. hyointestinalis. (C) *lpxA* gene PCR designed against the new "*Candidatus* Campylobacter infans" fecal metagenome strain with the 26 GEMS fecal DNA samples tested in panel B. Chl, C. hyointestinalis subsp. *lawsonii*; Chh, C. hyointestinalis subsp. *hyointestinalis*; G1, "*Candidatus* Campylobacter infans"; G2, 202699; G3, 203886; G4, 700541; G5, 302411; G6, 302176; G7, 700488; G8, 702610; G9, 702562; G10, 702298; G11, 700921; G12, 503818; G13, 700209; G14, 310426; G15, 703664; G16, 103067; G17, 110498; G18, 702556; G19, 704137; G20, 700270; G21, 700207; G22, 700173; G23, 100795; G24, 704231; G25, 704029; G26, 710603; NTC, no-template control. The first number of the 6-digit code indicates sample site (1, The Gambia; 2, Mali; 3, Mozambique; 5, India; 7, Pakistan). Download FIG S4, TIF file, 2.0 MB.
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\(A\) Functional categories for clusters of orthologous groups (COGs) in metagenomic sequencing. Percentages are based on the number of reads with predicted function. (B) Functional categories for subsystems in metagenomics. Percentages are based on the number of reads with predicted subsystem function. (C) Taxonomic abundance at the genus level. Abundances are based on the number of reads for each genus. (D) Taxonomic distribution in metagenomic samples at the order level. Percentages are based on the number of reads for each order. (E) Taxonomic distribution in metagenomic samples at the genus level. Percentages are based on the number of reads for each genus. (F) Taxonomic distribution of total metagenomic sequencing. Percentages are based on the amount of sequences of the assembled contigs. Download FIG S5, TIF file, 1.8 MB.
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Using the metagenomic sequencing data, we designed *lpxA* primers for "*Candidatus* Campylobacter infans" for comparison with the *lpxA* primers used for the multiplex PCR that we performed previously and tested all 26 fecal samples that had 16S rRNA predictions closest to C. hyointestinalis subsp. *lawsonii*/uncultured *Campylobacter*. The PCR results indicated that 18 of the 26 samples had the expected PCR product, except samples G8, G9, G19, G20, G24, G25, and G26 ([Fig. S4C](#figS4){ref-type="supplementary-material"}). For further confirmation, specific primers for the "*Candidatus* Campylobacter infans" full-length *atpA* gene were designed and used to amplify 20 of the remaining 25 samples. The phylogenetic tree constructed from the aligned amplicon and reference *atpA* sequences showed that the campylobacters in these 20 samples are very similar to "*Candidatus* Campylobacter infans" ([Fig. 4A](#fig4){ref-type="fig"}). Combining the *lpxA* and *atpA* results, 24 of 26 fecal samples were confirmed to contain "*Candidatus* Campylobacter infans," and 19 of them were from exclusively breastfed infants, while 5 were from nonbreastfed infants ([Fig. 4B](#fig4){ref-type="fig"}), from five out of the seven GEMS countries, including The Gambia, Mali, Mozambique, India, and Pakistan.

![Detection of "*Candidatus* Campylobacter infans" and prevalences of different *Campylobacter* species. (A) Phylogenetic analysis of "*Candidatus* Campylobacter infans" in GEMS samples using the full *atpA* gene. Red circles, *atpA* from GEMS fecal DNA (the first number of the 6-digit code indicates sample site \[1, The Gambia; 2, Mali; 3, Mozambique; 5, India; 7, Pakistan\]); red solid circle, "*Candidatus* Campylobacter infans" *atpA.* The dendrogram was constructed using the neighbor-joining algorithm and the Tamura three-parameter method. Bootstrap values of \>75%, generated from 1,000 replicates, are shown at the nodes. (B) Prevalences of different *Campylobacter* species in the study subjects, detected by 16S rRNA sequencing and confirmed by *lpxA* multiplex PCR and *atpA* sequencing (*atpA* sequencing was done only for "*Candidatus* Campylobacter infans").](mSphere.00735-19-f0004){#fig4}

As expected, genes encoding pathways for the utilization of amino acids and peptides, including amino acid transporters and peptidases, were identified in the "*Candidatus* Campylobacter infans" genome. The respiratory enzyme NADH:quinone oxidoreductase (also called complex I) is a major electron source in many bacteria, including C. jejuni ([@B33]), but all 14 *nuo* genes encoding complex I are absent in "*Candidatus* Campylobacter infans," suggesting that it depends on other electron donors, such as hydrogen and formate, unless single-protein NADH dehydrogenases serve the same purpose. Genes required for utilizing hydrogen and formate as electron donors were identified in the metagenome, including those encoding the \[Ni-Fe\]-type hydrogenase HydABC, a nickel uptake system, and a formate dehydrogenase that can oxidize formate and release protons and electrons. Virulence genes, including those encoding invasion antigens (*ciaB* and *ciaD*), the zonula occludens toxin (*zot*), an outer membrane fibronectin-binding protein (*cadF*), heavy metal resistance genes, a multidrug efflux pump (*cmeABC*), and other drug resistance transporters, are potentially part of the "*Candidatus* Campylobacter infans" genome. Also, "*Candidatus* Campylobacter infans" may express an S-layer since we detected the presence of an S-layer secretion system (*sapDEF*), without homologs of the surface layer proteins (*sapA* and *sapB*), but other proteins may be involved.

Prevalence and coinfection of *Campylobacter* spp. in GEMS. {#s2.6}
-----------------------------------------------------------

As expected, since we used a subset of GEMS samples that tested positive for C. jejuni or C. coli, C. jejuni is the most prevalent species among symptomatic and asymptomatic *Campylobacter* infections, colonizing nearly twice as many infants as the total of all other species (107 colonized with C. jejuni and 68 colonized with other species). However, it is interesting to note that several other *Campylobacter* species are found, including C. coli (24 infants), "*Candidatus* Campylobacter infans" (24), and C. upsaliensis (18), and the order of abundance is generally consistent when split into the four groups ([Fig. 4B](#fig4){ref-type="fig"}). Among the 131 infants with *Campylobacter* infections, 36 (27.5%) were coinfected with different *Campylobacter* species, and among these, 8 (6.1%) were coinfected with three *Campylobacter* species ([Table S4](#tabS4){ref-type="supplementary-material"}).
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DISCUSSION {#s3}
==========

In LMICs, diarrheal diseases are the second leading cause of mortality in children under 5 years of age, and infection with *Campylobacter* is one of the major causes of gastroenteritis in these children ([@B1], [@B2], [@B7], [@B34]). Previous studies suggest that breastfeeding protects infants from *Campylobacter-*induced diarrhea by reducing the ingestion of contaminated water/foods and lessening contact with unsanitary surroundings through closer interactions with the mother ([@B7], [@B12], [@B28]). In addition, breastfeeding increases exposure to fucosylated HMOs, particularly 2′-fucosyllactose in secretor mothers, which is predicted to act as a binding decoy to prevent C. jejuni colonization of the intestine ([@B11]). Yet exceedingly high rates of campylobacteriosis are reported among exclusively breastfed infants in LMICs ([@B7]). Consistent with these reports, our studies comparing 16S rRNA profiles of fecal DNA isolated from infants in GEMS show a trend of a higher *Campylobacter* abundance in exclusively breastfed than in nonbreastfed infants, leading us to evaluate the metabolic preferences among these isolates. We previously demonstrated that \>50% of sequenced C. jejuni isolates possess the *fuc* locus for [l]{.smallcaps}-fucose catabolism ([@B16]), and the possession of this pathway provides a competitive colonization advantage in the piglet model of diarrheal disease ([@B17]). Since C. jejuni lacks fucosidases, it grows only on fucose-modified gut oligosaccharides in the presence of other gut microbes, such as Bacteroides vulgatus, suggesting a scavenging lifestyle within the intestine ([@B35]). Many commensal bacteria in the gut, including *Bifidobacterium* and *Bacteroides*, possess fucosidases and are predominant in breastfed infants ([@B18][@B19][@B20]), suggesting that breastfeeding may benefit *fuc*^+^ C. jejuni strains, particularly since fecal levels of free [l]{.smallcaps}-fucose can reach milligram amounts in breastfed infants ([@B22]).

In this study, we indeed found high levels of *Bifidobacterium* in breastfed infants, as expected. However, we found that although nonbreastfed infants were colonized with equal proportions of [l]{.smallcaps}-fucose-metabolizing and -nonmetabolizing C. jejuni and C. coli strains, the proportion of strains unable to metabolize [l]{.smallcaps}-fucose increased significantly in exclusively breastfed infants, although we cannot exclude the possibility that some infants were colonized with multiple strains of these species. This was particularly evident when comparing infants with symptomatic infections, who exhibited 6-fold-higher levels of this organism. Thus, HMOs may indeed function as decoys for *Campylobacter fuc*^+^ strains, and this may correlate with our recent observation that the *fuc* locus protein Cj0485 is necessary for *Campylobacter* [l]{.smallcaps}-fucose chemotaxis ([@B16]) and new studies in our laboratory comparing chemotaxis and sugar adhesion illustrating differences between strains capable of sugar metabolism and asaccharolytic strains (H. Nothaft, unpublished data). However, these results also suggest that there is a selection for C. jejuni or C. coli strains that are better capable of thriving within the infant gut. In addition to HMOs, breast milk contains high quantities of proteins (especially caseins) and their breakdown products ([@B36]), which could promote the growth of campylobacters, particularly since even carbohydrate-utilizing C. jejuni strains prefer amino acids such as serine, glutamate, and aspartate over fucose, indicating the existence of a metabolic hierarchy ([@B35]). Thus, a preference for the proteinaceous components in breast milk may make [l]{.smallcaps}-fucose or [d]{.smallcaps}-glucose utilization irrelevant. Additionally, the quantities of free [l]{.smallcaps}-fucose could be smaller than expected if mothers are not secretors or produce smaller quantities of HMOs due to nutrient availability ([@B37], [@B38]). Glutamine is one of the most abundant free amino acids in human milk, and the possession of the γ-glutamyl transpeptidase (GGT) enzyme has been negatively correlated with the presence of the fucose pathway in C. jejuni ([@B29], [@B30]), but only 15% of the isolated C. jejuni and C. coli strains lacking *fuc* examined in this study contain the *ggt* gene (lower than the 31% expected) ([@B39]), so it is likely that other carbon sources from breast milk fuel the metabolism of the isolated *Campylobacter* strains. In addition to C. jejuni and C. coli, "*Candidatus* Campylobacter infans" was also detected nearly three times as frequently in exclusively breastfed infants as in nonbreastfed infants, and the metagenomic data identified pathways for amino acid and peptide utilization, without any obvious clusters for carbohydrate metabolism. Based on the unexpected observation that exclusive breastfeeding increases the *Campylobacter* abundance in infants \<1 year of age, more studies are needed to assess the effect of breast milk on *Campylobacter* infection, particularly since a recent study in preterm pigs fed human milk oligosaccharides showed increased levels of *Proteobacteria* dominated by *Campylobacter* and *Helicobacter* with longer HMO exposure ([@B40]). In particular, targeted epidemiological studies are required to determine whether higher *Campylobacter* levels are correlated with more severe dysenteric diarrhea. While C. jejuni or C. coli strains were isolated from all infants included in our study, 16S rRNA analysis did not detect *Campylobacter* in all the corresponding fecal DNA samples. This is consistent with our previous studies on chicken gut microbiome compositions that demonstrated that C. jejuni cannot be detected by 16S rRNA sequencing when \<10^5^ CFU per g of cecal content are present ([@B41], [@B42]) and with studies by other groups that found that culture-based methods need to be used for bacteria present at levels below the detection threshold (\<10^6^ CFU/g feces) to surpass the "depth bias" of genomic approaches ([@B43], [@B44]).

C. jejuni and C. coli are the two most commonly isolated pathogenic *Campylobacter* species worldwide ([@B8]); however, recently emerging non-C. jejuni/C. coli *Campylobacter* species have also been associated with gastrointestinal diseases and diarrhea ([@B15]). Here, we show that C. jejuni and C. coli are the predominant *Campylobacter* species in infants \<1 year of age in GEMS, and non-C. jejuni/C. coli campylobacters, especially "*Candidatus* Campylobacter infans" and C. upsaliensis, are also prevalent in this age group. The prevalence of other *Campylobacter* species may be underestimated in this study since only fecal samples positive for C. jejuni and C. coli were included. Nonetheless, the new species "*Candidatus* Campylobacter infans" is detected at the same level as C. coli and accounts for approximately 1.6% of the fecal microbiome in exclusively breastfed infants with diarrhea and, in one extreme case, 83% of the total fecal microbiome, which suggests that "*Candidatus* Campylobacter infans" can be a relevant pathogen in infants. As the third most prevalent *Campylobacter* species in this study, C. upsaliensis has been previously reported to cause diarrhea in humans ([@B45]), and a recent study demonstrated that non-C. jejuni/C. coli species, such as C. hyointestinalis, account for more *Campylobacter* infections in children \<2 years of age in Peru ([@B15], [@B46]). In the present study, coinfection with multiple *Campylobacter* species is not uncommon, which provides more opportunities for genomic rearrangements between campylobacters to escape selective pressures and alter virulence properties ([@B47]). Taken together, our data indicate that vaccines to prevent *Campylobacter* infection should not only focus on eliminating C. jejuni and C. coli but also consider other nonthermophilic species, including "*Candidatus* Campylobacter infans" and C. upsaliensis, for preventing diarrheal disease in infants in LMICs ([@B42], [@B48]). However, among all the infants with *Campylobacter* infection (both symptomatic and asymptomatic), approximately 16% are infected solely with *Campylobacter*, and 84% showed comorbidities with other diarrheal pathogens (viruses, other bacteria, and parasites), including 67% of infants diagnosed with *Campylobacter*-related diarrhea. Many studies have reported that coinfection with multiple intestinal pathogens is common in infants in LMICs, and one proteobacterial infection (such as Escherichia coli, *Salmonella*, and *Campylobacter*) increases the host's susceptibility to other *Proteobacteria* (i.e., the proteobacterial bloom), so this should be kept in mind when considering the correlations observed in this study ([@B1], [@B49], [@B50]). Overall, our results indicate that approaches to control the risk of infection by other intestinal pathogens, such as sanitization, water treatment, and vaccination, are important to reduce diarrheal diseases in low-resource settings, but microbial gut compositions may also play a role.

In this study, we demonstrate that infants with diarrhea had the lowest fecal microbial diversity, consistent with data from previous studies that showed that diarrheal disease decreases the diversity of the gut microbiome ([@B51]). Diarrhea-free controls had significantly higher gut microbial diversity, which shows that asymptomatic *Campylobacter* infection does not devastate the gut microbiota as seen in diarrheal cases. When comparing cases and controls, the levels of several different genera were significantly elevated in controls among both exclusively breastfed and nonbreastfed infants, most of which were negatively correlated with *Campylobacter* yet positively correlated with each other, including *Blautia* and *Dorea*, *Blautia* and *Faecalibacterium*, and *Erysipelatoclostridium* and the Ruminococcus gnavus group. Among these genera, *Blautia* has been observed to have beneficial anti-inflammatory effects in illnesses such as graft-versus-host disease ([@B52]); however, other co-occurring bacteria (such as Faecalibacterium prausnitzii) may also protect against diarrhea ([@B53]), indicating that more studies need to be done to explore the potential protective roles of other microbes in diarrheal diseases.

Overall, our study points to the need to further explore the contributions of emerging pathogens such as "*Candidatus* Campylobacter infans" and C. upsaliensis to diarrheal disease in infants in LMICs and the potentially protective roles of intestinal bacteria, particularly those of the *Blautia* genus, that are associated with asymptomatic *Campylobacter* carriage. We also report the unexpected observation that a greater *Campylobacter* abundance is detected in exclusively breastfed infants with diarrheal disease, and further epidemiological studies with corroborating experimental work are warranted. These infants show a reduced incidence of infection with C. jejuni and C. coli fucose-utilizing strains, suggesting that HMOs may indeed function as decoys for *fuc*^+^ strains but also select for strains with metabolic properties that render them more capable of thriving in the infant gut. Current studies are focused on the interplay between C. jejuni chemotaxis, binding, and metabolism in exclusively breastfed infants and the development of inexpensive novel intervention and treatment strategies.

MATERIALS AND METHODS {#s4}
=====================

Samples. {#s4.1}
--------

Fecal DNA samples were obtained from GEMS or the follow-up study GEMS1a, and the study design and methodology were previously described ([@B24]). Briefly, GEMS was a prospective case-control study of moderate-to-severe diarrhea (MSD) in children under 5 years of age conducted between 1 December 2007 and 3 March 2011 in seven low- and middle-income countries: The Gambia, Kenya, Mali, Mozambique, Bangladesh, India, and Pakistan. Cases with acute diarrhea were included, each representing a new episode and meeting at least one criterion of MSD (sunken eyes, loss of skin turgor, initiation of intravenous rehydration, dysentery, or hospitalization with diarrhea or dysentery). Controls had no diarrhea in 7 days and were included in the same demographic surveillance system area with cases and matched cases in age, sex, residence, and time. Illness management strategies, including feeding, fluid administration, and breastfeeding practices (no breastfeeding, partly breastfeeding, and exclusively breastfeeding), were queried from the caretakers. A follow-up study called GEMS1a also enrolled children with MSD as well as children with less-severe diarrhea (LSD) (acute diarrhea without signs of MSD) and matched controls from 31 October 2011 to 14 November 2012, using essentially the same methodology as the one for GEMS. To study the spread of *Campylobacter* and the effect of breastfeeding on campylobacteriosis, we included DNA samples isolated from stools of cases (both MSD and LSD) and controls under 1 year of age, whose caretakers indicated that they were exclusively breastfed or not breastfed (infants who were still breastfed but also received complementary food were excluded from the analysis), with *Campylobacter* isolated from the fecal samples using selective Campy-BAP plates for cephalothin-resistant *Campylobacter* species, including most C. jejuni and C. coli strains, grown at 42°C for 3 days. Subsequently, one single colony per sample was subcultured and used in this study ([@B9]).

16S rRNA sequencing and data analysis. {#s4.2}
--------------------------------------

The V6-V8 and V4 hypervariable regions of the 16S rRNA gene were amplified from fecal DNA using universal primers described previously ([@B42], [@B54]). The amplification products were cleaned up, normalized, barcoded, and sent to the Georgia Genomics and Bioinformatics Core (GGBC) for sequencing using the Illumina MiSeq PE300 kit. Normalization was based on the double-stranded DNA (dsDNA) concentration detected by using the NanoDrop One^C^ system (Thermo Scientific) and a Qubit 2.0 fluorometer (Thermo Scientific). A total of 12,387,812 sequences were obtained, with a median of 53,166 sequences per sample. DADA2, an open-source software package for modeling and correcting Illumina-sequenced-amplicon errors, was used in QIIME2 to filter, trim, dereplicate, and join the yielded paired-end sequences and construct an amplicon sequence variant (ASV) table for further analysis ([@B55][@B56][@B57]). The alpha diversity of the fecal microbiome was calculated using the Shannon index in QIIME2. Vsearch was used to cluster representative sequences against the SILVA SSU r128 database with 99% identity ([@B58]) to known operational taxonomic units (OTUs). Correlation between microbial OTUs was calculated using SparCC, a method to estimate correlation values from compositional data ([@B59]).

Fucose permease gene (*fucP*) and γ-glutamyl transpeptidase gene (*ggt*) screening and [l]{.smallcaps}-fucose/[d]{.smallcaps}-glucose utilization experiments with C. jejuni and C. coli strains. {#s4.3}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To identify the potential fucose utilization ability of *Campylobacter* strains isolated in GEMS, we screened for the *fucP* gene in all GEMS-isolated *Campylobacter* strains (C. jejuni and C. coli) by colony or genomic DNA PCR using primers designed to amplify the *fucP* gene of C. jejuni NCTC 11168 (fucP-F/R \[CAT GAA AGT GGC TTT TTA CAG/ATT TTT TTC ATC ACC AAG CTT TG\]) in a multiplex format with 16S rRNA control primers (16S-F/R \[AAT GGC TTA ACC ATT AAA CTG C/AAC TAA ATA CGT GGG TTG CG\]), which was confirmed to also work for C. coli strains (data not shown). To verify that a *fucP* PCR product corresponded to a strain's ability to use fucose, we performed growth experiments in a subset of the strains lacking *fucP* and all *fucP*^+^ strains as described previously ([@B16]). Briefly, *Campylobacter* strains were adjusted to an optical density at 600 nm (OD~600~) of 0.05 and inoculated into 5 ml MEMα (minimum essential medium α; Thermo Fisher Scientific) (with 20 μM iron added) with or without 25 mM [l]{.smallcaps}-fucose. The inoculated culture was incubated microaerobically at 37°C for 18 h, and the OD~600~ was measured using the NanoDrop One^C^ system (Thermo Scientific). Screening for the *ggt* gene was carried out as previously described ([@B29]). To test for [d]{.smallcaps}-glucose utilization, we performed growth experiments as described above, using a random subset of 33 strains in DMEM (Dulbecco's modified Eagle's medium) without glucose (Thermo Fisher Scientific), and the strains were incubated microaerobically for 48 h. Campylobacter cuniculorum LMG 24588 was used as the positive control.

Verification of C. jejuni, C. coli, C. upsaliensis, C. lari, and C. hyointestinalis. {#s4.4}
------------------------------------------------------------------------------------

Representative sequences of 16S rRNA (V6-V8) of *Campylobacter* classified by Scikit-learn ([@B60]) in QIIME2 were aligned and classified using SINA with the SILVA SSU r128 database, and bacterial species with a 0.99 minimum identity to the query sequence were obtained ([@B61]). A multiplex PCR of the lipid A biosynthesis gene *lpxA* was used to confirm the presence of C. jejuni, C. coli, C. upsaliensis, and C. lari in fecal DNA, as previously described ([@B31]). A novel *lpxA* forward primer was designed here for C. hyointestinalis (lpxAC.hyo \[CAA AGA CGC GGT TTT GGG CGA TGA AGT CGT GG\]). This primer is compatible with the *lpxA* primers described previously ([@B31]), yielding (in conjunction with the previously described reverse primer) a product of 285 bp. The lpxAC.hyo and lpxARKK2m primer set was used to verify the presence of C. hyointestinalis (both subspecies) in fecal DNA.

Detection of a new *Campylobacter* species. {#s4.5}
-------------------------------------------

Illumina reads were initially trimmed to remove adapters and quality filtered (\>Q20) using Trimmomatic (v0.39) ([@B62]), and human genome contamination was then removed by mapping reads to the human GRCh37/hg19 reference genome with Bowtie2 (v2.1.0) ([@B63]). Next, filtered reads were submitted to MG-RAST ([@B64]) for gene function prediction and taxonomic abundance determination, while the reads were assembled and the taxonomic abundance was confirmed using the following programs: metaSPAdes (assembly; v3.12.0) ([@B65]), Kraken2 (taxonomic abundance; v2.0.8) ([@B66]), and Bracken (taxonomic abundance; v2.0.0) ([@B67]). The metaSPAdes assembly resulted in 33 contigs identified as *Campylobacter*, including 24 contigs of \>5,000 bp, while an additional assembly with Newbler (v2.6) yielded 75 contigs identified as *Campylobacter*, including 56 contigs of \>5,000 bp. Both sets of assembled *Campylobacter* contigs from metaSPAdes and Newbler were independently analyzed for completeness and contamination using CheckM software (v1.0.12) ([@B68]), which demonstrated that the 33 contigs from metaSPAdes were 94.2% complete, with 4.9% contamination, whereas the 75 contigs from Newbler were 98.5% complete, with only 0.19% contamination (classified as an extremely low level of contamination and within the margin of error for the CheckM software). Therefore, all additional metagenomic *Campylobacter* analyses were conducted with the contigs from the Newbler assembly. Coding sequences present within the 75-contig set were determined using GeneMark ([@B69]). A custom protein database was constructed, which combined the proteomes derived from all currently validated (and fully annotated) *Campylobacter* and *Arcobacter* genomes (one to six proteomes per taxon) present in GenBank. The metagenomic proteome was compared to this custom database through an all-versus-all pairwise BLASTP analysis. Genes within the metagenome were assigned a function based on matches above the minimum requirement of 40% similarity and where the match length was ≥75% of the subject and query protein lengths. The sequences of 20 core genes (*aroC*, *atpA*, *dnaN*, *eno*, *fabH*, *frr*, *glnA*, *groEL*, *hemB*, *ileS*, *lpxA*, *miaB*, *mrp*, *nrdB*, *pnp*, *prfA*, *queA*, *speA*, *spoT*, and *tkt*) and their cognate proteins were extracted from the metagenome and 50 *Campylobacter*, *Arcobacter*, and *Sulfurospirillum* genomes. These gene and protein sets were concatenated in the order mentioned above for each genome and aligned using CLUSTALX. Neighbor-joining phylogenetic trees were constructed using MEGA v6 ([@B70]): the nucleotide tree was constructed using the Kimura two-parameter model, and the amino acid tree was constructed using the Poisson model. Additionally, the 75 *Campylobacter* contigs were concatenated and used for an average nucleotide identity (ANI) analysis ([@B71]), along with the genomes of 45 *Campylobacter*, *Arcobacter*, *Sulfurimonas*, *Sulfurospirillum*, and *Helicobacter* taxa. Using the metagenome sequence, novel *lpxA* (lpxAC.GEMS \[GCA AAA AGC AGT GGC GAG GGT TG\], compatible with lpxARKK2m) and *atpA* (atpA-F/R \[GTG AGC GCA AAA TTA AAA GCA G/TTA TTC AGC ACT AAA AGT AGC C\]) primers were designed and used to verify the presence of this putative new *Campylobacter* species in the other 25 fecal samples. The *atpA* sequences were aligned using CLUSTALW, and neighbor-joining phylogenetic trees were constructed with MEGA v7 using the Tamura three-parameter method ([@B72]).

Statistics. {#s4.6}
-----------

For analysis of the fecal microbiome, a Kruskal-Wallis test was used to compare alpha diversity values between different groups; differences in the relative abundances of bacterial phyla between groups were calculated by a Kruskal-Wallis H test and corrected by the false discovery rate (FDR) in STAMP ([@B73]). For analysis of strains capable of metabolizing fucose, a chi-square test was used to determine if the proportion of samples that can metabolize fucose in both cases and controls significantly differed from 50%.

Data availability. {#s4.7}
------------------

The metagenome containing "*Candidatus* Campylobacter infans" can be found in the NCBI database (accession number [SPMW00000000](https://www.ncbi.nlm.nih.gov/nuccore/SPMW00000000)). The 16S rRNA sequencing data can also be found in the NCBI database under the following accession numbers: V4 data ([PRJNA596502](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA596502)); V6-V8, samples 1-100, data ([PRJNA596501](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA596501)); V6-V8, samples 101-233, data ([PRJNA596500](https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA596500)).
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